CG ONCOLOGY INC

CG Oncology insider POST Leonard trades $0.60 buy, $74.54 sell, and option cash‑out – revealing bullish confidence amid a fast‑growing bladder‑cancer pipeline.

CG Oncology insider James Mulay buys shares at one‑third the market price yet sells at a premium—insight into his confident, disciplined trading strategy and the company’s upside potential.

CG Oncology insider Post’s disciplined 10b5‑1 buy‑sell moves signal confidence, not distress, amid a 19% weekly rally and bullish pipeline buzz.

Leonard Post’s recent buy‑sell cycle at CG Oncology shows insider confidence yet short‑term focus—what does it mean for investors?

CG Oncology insider activity shows coordinated stock option grants and exercises, hinting at executive confidence and potential upside tied to future product milestones.

CG Oncology insider buying signals optimism amid a surge in social buzz—learn what director Liu Guan‑Chyun’s recent option exercise means for investors.

CG Oncology insiders, including the CEO and COO, amass 550,000+ shares via cost‑free options—showing confidence in upcoming clinical and licensing milestones that may support stock price.

CG Oncology CEO’s bulk buy at $1.72 signals a bullish insider cue, hinting at upcoming trial results that could propel the stock beyond its 52‑week high.

CEO Kuan Arthur’s recent CG Oncology stock purchase signals insider confidence—learn what this means for investors and future valuation prospects.

Mulay James’s strategic buy‑low, sell‑high trades in CG Oncology stock reveal insider confidence and long‑term upside, balancing liquidity with future value.